Novartis, Roche, and Pfizer respond to FDA Biosimilar Action Plan
Major pharmaceutical firms Novartis, Roche, and Pfizer have reacted to the US FDA’s Biosimilar Action Plan, which aims to “strike a balance” between innovation and market competition.
Top Headlines
Global Industry News
-
UK vote to keep EMA ties will likely instil confidence in industry, says RAPS
from in-PharmaTechnologist.com
-
Concept registers across the pond to offer pharma testing for US market
from Outsourcing-Pharma.com
-
3D printing brings novel doses, shapes and characteristics to ‘advanced manufacturing’, states Aprecia
from in-PharmaTechnologist.com
-
A call for action: IAOCR urges CROs support more high throughput research centres in UK
from Outsourcing-Pharma.com
Hot Topics
-
Mylan becomes latest to strike licensing deal with AbbVie for Humira biosimilar
Biosimilars
-
Samsung BioLogics adjudged to have violated accounting standards
Biosimilars
-
T cell cytokine ‘backpacks’ target solid tumours
Pipelines
-
Novartis selects French CDMO to make CAR T-cell therapies
Cell & Gene Therapies
